AstraZeneca
AZN
1,408 hedge funds and large institutions have $46.4B invested in AstraZeneca in 2025 Q4 according to their latest regulatory filings, with 266 funds opening new positions, 500 increasing their positions, 411 reducing their positions, and 120 closing their positions.
122% more first-time investments, than exits
New positions opened: 266 | Existing positions closed: 120
42% more call options, than puts
Call options by funds: $597M | Put options by funds: $420M
22% more capital invested
Capital invested by funds: $37.9B → $46.4B (+$8.5B)
22% more repeat investments, than reductions
Existing positions increased: 500 | Existing positions reduced: 411
9% more funds holding
Funds holding: 1,289 → 1,408 (+119)
5% more funds holding in top 10
Funds holding in top 10: 21 → 22 (+1)
0.34% more ownership
Funds ownership: 15.93% → 16.26% (+0.34%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$1.17B |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$420M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$412M |
| 4 |
Harris Associates
Chicago,
Illinois
|
+$327M |
| 5 |
Citigroup
New York
|
+$204M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$924M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$831M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$550M |
| 4 |
Primecap Management
Pasadena,
California
|
-$258M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$241M |
AZN Hedge Fund Activity: Q4 2025 in Review
1,408 of the 8,284 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q4 2025, worth a combined $46.4B — up 22% from $37.9B a quarter earlier.
Buyers outnumbered sellers: 266 funds opened new AZN positions and 120 closed out — a net gain of 146 holders — while 500 added to existing stakes and 411 trimmed.
The largest buyer was Invesco, adding an estimated $1.17B. The largest seller was Capital International Investors, cutting an estimated $924M.
- 1,408 institutional investors held AstraZeneca (AZN) as of Q4 2025, up from 1,289 in Q3 2025.
- Funds reported $46.4B of AstraZeneca stock for Q4 2025, up 22% quarter-over-quarter.
- 266 funds opened new AstraZeneca positions in Q4 2025 and 120 closed out, a net change of +146 holders.
- The largest AstraZeneca buyer in Q4 2025 was Invesco, an estimated $1.17B added.
- The largest AstraZeneca seller in Q4 2025 was Capital International Investors, an estimated $924M sold.
Based on aggregated 13F filings for Q4 2025.